Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Nuvalent, Inc.NASDAQ: NUVL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $83.61M rose 12.3% year over year, behind the +24.7% change in trailing-twelve-month research & development. Sequentially, it rose 23.3% from the prior quarter. Over 3 fiscal years it compounded at +68.9% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +12.3% toward the trailing-twelve-month pace of +24.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 306.97M USD
- Year-over-year change
- +41.0%
- 4-year CAGR
- +71.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 306.97M | +41.0% |
| FY2024 | 2024-12-31 | 217.77M | +92.3% |
| FY2023 | 2023-12-31 | 113.24M | +77.7% |
| FY2022 | 2022-12-31 | 63.73M | +79.2% |
| FY2021 | 2021-12-31 | 35.56M | — |
Research & Development vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.7% is the 2nd highest of 9, against a peer median of +4.8%.
- Over three fiscal years its annual growth of +68.9% compares with a peer median of +24.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.03B USD | +74.2% | +67.4% | — | |
| LTM Sep 2026 | $739.14M USD | +21.7% | +29.3% | 164.0% | |
| LTM Sep 2026 | $623.61M USD | -26.8% | +9.9% | 13.2% | |
| LTM Jun 2026 | $394.1M USD | +0.9% | +19.0% | 555.4% | |
| LTM Mar 2026 | $316.16M USD | +24.7% | +68.9% | — | |
| LTM Sep 2026 | $283.28M USD | +1.6% | -16.9% | 1125.4% | |
| LTM Jun 2026 | $187.86M USD | -3.5% | +46.8% | 24.2% | |
| LTM Sep 2026 | $179.67M USD | +7.9% | +15.5% | 64.0% | |
| FY2025 | €177.76M EUR | +21.3% | +54.4% | — | |
| Peer median (excluding NUVL) | — | +4.8% | +24.1% | 114.0% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.56M | 63.73M | 113.24M | 217.77M | 306.97M |
| Selling, General & Admin | 10.26M | 22.38M | 36.25M | 62.59M | 107.34M |
| Operating Expenses | 45.82M | 86.11M | 149.49M | 280.37M | 414.31M |
| Depreciation & Amortization | 215K | 0 | 0 | 280.37M | 414.31M |
| EBITDA | (46.12M) | (81.85M) | (126.22M) | 20.38M | (10.49M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.82M) | (86.11M) | (149.49M) | (280.37M) | (414.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 23.27M | 38.32M | 44.74M |
| Interest Expense | 0 | 0 | 23.27M | 0 | 0 |
| Other Income / Expenses | (521K) | 4.25M | 23.27M | 20.38M | (10.49M) |
| Income Before Tax | (46.34M) | (81.85M) | (126.22M) | (259.99M) | (424.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 764K | 585K |
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| EPS (Diluted) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| Weighted Avg Shares | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
| Weighted Avg Shares (Diluted) | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.